Harbin Honor Pharmaceutical Co., Ltd.
Securities Code: 002437 Securities Abbreviation: Honor Pharmaceutical Announcement No.: 2026-03
Harbin Honor Pharmaceutical Co., Ltd. Report of the Board of Directors' Audit Committee on the Supervision of the Accounting Firm's Performance in 2025
In accordance with the "Company Law," "Securities Law," "Measures for the Selection of Accounting Firms by State-owned Enterprises and Listed Companies," "Shenzhen Stock Exchange Listed Company Self-regulatory Supervision Guide No. 1 - Standardized Operation of Main Board Listed Companies," and other laws, regulations, normative documents, and the "Articles of Association," the Company's Board of Directors' Audit Committee, with a principle of diligence and responsibility, has conscientiously performed its duties. The following is a report on the Audit Committee's supervision of the accounting firm's performance by Shangshi Certified Public Accountants (Special General Partnership) (hereinafter referred to as "Shangshi Firm") in 2025:
I. Basic Information of the Board of Directors' Audit Committee
In February 2025, the Company completed the election of the Board of Directors. The Company's Audit Committee is composed of independent director Ms. Wang Lida, independent director Mr. Chen Yi, and Chairperson Ms. Shen Zhenyu. Ms. Wang Lida serves as the Chairperson of the Audit Committee. The composition, professional knowledge, and work experience of the Audit Committee members meet relevant regulatory requirements and company regulations.
II. Procedures for Appointing the Accounting Firm
On April 24, 2025, the Company held the third meeting of the Seventh Board of Directors, which deliberated and approved the "Proposal on Re-appointing Shangshi Certified Public Accountants (Special General Partnership) as the Company's External Auditor for 2025." This proposal was approved by the 2024 Annual General Meeting of Shareholders on May 16, 2025.
Before being submitted to the Board of Directors for deliberation, the aforementioned proposal was previously reviewed and unanimously approved by the third meeting of the Seventh Board of Directors' Audit Committee on April 14, 2025.
III. Performance of the Accounting Firm